Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Tarsons Products Ltd

₹ 230-0.10%
06 Jan – close price
🔗tarsons.com•BSE: 543399•NSE: TARSONS
Market Cap₹ 1,225 Cr.
Current Price₹ 230
High / Low₹ 458
Stock P/E36.6
Book Value₹ 124
Dividend Yield0.00 %
ROCE8.57 %
ROE6.71 %
Face Value₹ 2.00
Sales₹ 321 Cr.
OPM35.3 %
Mar Cap₹ 1,225 Cr.

ABOUT

Tarsons Products Ltd. (TPL) is an Indian labware company engaged in thedesigning, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others'including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals[1]

KEY POINTS

India’s Leading Labware Company[1]One of the leading Indian labware company engaged in designing, development, manufacturing and marketing of consumables, reusables and others (including benchtopequipment & instruments)

Also present in buckets:
Aggressive Growth TriggersRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsJv Partnerships AcquisitionsRevenue Guidance Vs ActualsCredit Rating UpdatesRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Poly Medicure1787.6050.0618119.020.2091.805.02443.885.6820.081712.1326.54361.9891.846.2113.230.08
2.Fischer Medical41.43133.802686.800.0113.902928.2686.31117.621.08170.6713.7020.0813.937.460.440.08
3.Laxmi Dental259.9055.451428.470.008.5344.8272.2726.5219.20260.2116.1725.768.536.2312.310.04
4.Tarsons Products230.2836.641225.230.006.53-49.5080.510.498.57320.9935.2833.446.531.854.400.41
5.Vasa Denticity591.9063.461026.170.004.99-7.0872.7222.4423.17268.377.9316.174.996.0014.510.00
6.OSEL Devices544.3535.37963.210.0015.1989.64146.8668.1331.14245.9818.1427.2315.195.4413.530.56
7.Prevest Denpro491.0029.60589.350.205.5715.0818.6614.7625.2567.8535.3719.915.575.0917.540.00
–Median: 13 Co.279.236.75589.350.05.5728.4664.2621.019.2170.6716.6619.915.575.2712.310.08

Quarterly Results

Standalone figures in ₹ crores

Dec 2022Dec 2023Dec 2024Jun 2023Jun 2024Jun 2025Mar 2023Mar 2024Mar 2025Sep 2022Sep 2023Sep 2024Sep 2025
Sales
61.3261.7976.1662.5764.8571.2882.0586.6493.0471.2566.3280.1280.51
Expenses
34.6538.9048.2441.2747.8349.0542.7952.7756.0738.5540.9456.6254.37
Operating Profit
26.6722.8927.9221.3017.0222.2339.2633.8736.9732.7025.3823.5026.14
Other Income
3.363.382.122.264.864.582.175.936.373.712.6010.657.32
Profit before tax
21.5913.7010.3012.858.724.7831.0925.5121.3428.7717.3217.518.88
Tax %
25.34%26.42%26.12%25.29%25.80%25.10%26.57%26.34%26.34%25.44%26.10%26.21%26.46%
Net Profit
16.1210.077.619.606.463.5722.8218.7815.7321.4612.8012.936.53
EPS in Rs
3.031.891.431.801.210.674.293.532.964.032.412.431.23

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
179176229301283277314321
Expenses
107107125148153174209208
Operating Profit
7269103153130103105113
Other Income
645812142420
Interest
76344101817
Depreciation
1514142229385471
Profit before tax
565392135109695845
Net Profit
39416910181514333
EPS in Rs
2,027.062,108.743,583.2518.9215.179.638.036.29
Dividend Payout %
0%0%0%0%0%21%0%–

Compounded Profit Growth

10 Years:%
5 Years:1%
3 Years:-25%
TTM:-31%

Compounded Sales Growth

10 Years:%
5 Years:12%
3 Years:1%
TTM:9%

Return on Equity

10 Years:%
5 Years:15%
3 Years:10%
Last Year:7%

Stock Price CAGR

10 Years:%
5 Years:%
3 Years:-31%
1 Year:-45%

Balance Sheet

Standalone figures in ₹ crores

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
0.190.200.191111111111
Reserves
135197244479559610642652
Borrowings
65363422111257231275
Other Liabilities
121518334676107140
Total Liabilities
2122492965447269539911,077
Fixed Assets
8992120189225252460509
Gross Block
103.51120.70162.81252.64316.46381.69643.44–
Accumulated Depreciation
14.5528.6642.3863.8591.61129.89183.58–
CWIP
7192232119267233251
Investments
0000001313
Other Assets
116137153323382434285304
Total Assets
2122492965447269539911,077

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
5164688376105110
Cash from Investing Activity
-34-26-64-138-179-296-52
Cash from Financing Activity
-18-14-2713085136-54
Net Cash Flow
-025-2375-18-554

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
91797579859486
Inventory Days
333365277478642528419
Days Payable
14443575544236
Cash Conversion Cycle
409400317482672580469
Working Capital Days
86110108150166-2437
ROCE %
–27%37%35%19%10%9%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
47.31%47.31%47.31%47.31%47.31%47.31%47.31%47.31%47.31%47.31%47.31%47.31%
FIIs
9.60%9.16%8.64%7.85%6.83%8.16%7.95%8.04%7.51%9.53%9.14%5.82%
DIIs
8.52%8.45%7.38%3.15%2.60%0.17%0.11%0.21%0.51%0.30%0.04%0.08%
Public
34.59%35.09%36.67%41.68%43.27%44.36%44.63%44.45%44.69%42.89%43.50%46.79%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Tarsons Products Appoints New Head of Revenue for India & APAC

15th April 2026, 12:08 am

Tarsons Products Completes EUR 300,000 Investment in Singapore Subsidiary

9th April 2026, 11:15 pm

Tarsons Products Appoints Mr. Vinesh Mohan Kriplani as Non-Executive Independent Director

8th April 2026, 10:37 pm

Tarsons Products Ltd: Special Resolution Passed for Appointing Independent Director via Postal Ballot

8th April 2026, 10:31 pm

Tarsons Products' Credit Rating Reaffirmed for Bank Facilities

31st March 2026, 11:19 pm

Published by Other Websites

External media mentions & references

US Tariff Threat Hits Indian Pharma Stocks Hard, Index Down 3%

2nd April 2026, 11:10 am

Stocks to Watch: Whirlpool Block Deal, Paytm RBI License, Wipro AI Breakthrough! Plus Earnings & More!

27th November 2025, 7:15 am

Stocks in Focus: Torrent Power, Adani Power Secure Major Power Plant Orders; BHEL Signs Defense Tech Deal; Aurobindo Pharma Gets FDA Observations

1st September 2025, 7:35 am

Cricketer Rohit Sharma Sells Stake; Polunin Fund Buys in Advanced Enzyme

29th August 2025, 9:44 pm

Tarsons Products Sees Revenue Growth, But Profits Hit by Expansion Costs

News Articles

Editorial & research coverage

Stocks to Watch: Whirlpool Block Deal, Paytm RBI License, Wipro AI Breakthrough! Plus Earnings & More!
Stocks to Watch: Whirlpool Block Deal, Paytm RBI License, Wipro AI Breakthrough! Plus Earnings & More!

27th November 2025, 7:15 am

Tarsons Products Commissions New Plant, Eyes FY27 Growth Surge
Tarsons Products Commissions New Plant, Eyes FY27 Growth Surge

Documents

Announcements

Closure of Trading Window
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Further Investment In Tarsons Life Science Pte. Ltd., A Wholly-Owned Subsidiary Of The Company.

27 Nov 2025 - Infused EUR 3,000,000 (1,000 shares at EUR3,000) into Singapore subsidiary to repay loans.

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

19 Nov 2025 - Nov 13, 2025 earnings call transcript uploaded; Q2 standalone revenue INR81 crore, H1 INR152 crore, EBITDA growth.

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

14 Nov 2025 - MUFG sold 1,092,519 shares (2.05%), reducing holdings to 5.28% as of Nov 12, 2025.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Credit Ratings

Rating update

20 Jun 2025 from care

Rating update

3 Feb 2025 from care

Rating update

2 Jan 2024 from care

Rating update

7 Nov 2022 from care

Rating update

29 Mar 2022 from care

Rating update

23 Mar 2021 from care

Concalls

Nov 2025

TranscriptPPTRecording

Aug 2025

TranscriptPPT

Jun 2025

TranscriptPPTRecording

Feb 2025

TranscriptPPTRecording

Nov 2024

TranscriptPPTRecording

Aug 2024

TranscriptPPTRecording

Aug 2024

PPT

Jun 2024

TranscriptPPT

Feb 2024

TranscriptPPTRecording

Feb 2024

PPT

Dec 2023

TranscriptRecording

Nov 2023

TranscriptPPTRecording

Aug 2023

TranscriptPPT

Jun 2023

TranscriptPPT

Feb 2023

TranscriptPPT

Nov 2022

TranscriptPPT

Aug 2022

TranscriptPPT

Jun 2022

TranscriptPPT

Feb 2022

TranscriptPPT

Stock Analysis

Description

  1. Tarsons Products Ltd. is an Indian labware company engaged in designing, developing, manufacturing, and marketing of consumables, reusables, and other lab equipment for research, academia, pharmaceutical, and diagnostic sectors.

Key Growth Triggers

  1. Expansion of manufacturing capacities at Panchla and Amta facilities, introduction of new product lines including cell culture and robotic consumables, and leveraging operating leverage as new capacities ramp up are key growth drivers. The company aims to double its addressable market with these initiatives.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. Profitability in Q2 FY26 was impacted by increased depreciation and finance costs. Net debt has increased, and the company faces export headwinds due to global economic conditions and US tariffs. A customs adjudication order has been received, though management expects no material impact.

Key Dates To Watch

  1. Submission of certificate under Regulation 74(5) for the quarter ended December 31, 2025, was on January 8, 2026. Upcoming Q3 FY26 results announcement dates are awaited.

Corporate Announcements

14th Apr 26
Impact Rating: 7
Tarsons Products Limited has appointed Mr. Mani Kalyan Dusi as its new Head – Revenue (India & APAC), designated as Senior Management Personnel. He brings extensive industry experience and is expected to join by May 20, 2026.
9th Apr 26
Impact Rating: 6
Tarsons Products has completed an equity investment of EUR 300,000 in its Singapore subsidiary, Tarsons Life Science Pte. Ltd., a Special Purpose Vehicle with Nil turnover.
8th Apr 26
Impact Rating: 6
Shareholders of Tarsons Products Limited have approved the appointment of Mr. Vinesh Mohan Kriplani as a Non-Executive Independent Director. His tenure of five years begins effectively from February 06, 2026.
8th Apr 26
Impact Rating: 6
Tarsons Products Limited successfully conducted a postal ballot for shareholders to vote on appointing Vinesh Mohan Kriplani as Non-Executive Independent Director. The resolution passed with 99.99% of votes in favour, confirming the appointment.
31st Mar 26
Impact Rating: 7
Tarsons Products Limited announced a reaffirmation of credit ratings by CARE for bank loan facilities. Key facilities include ₹500.73 crore (reduced from ₹516.02 crore) and ₹24.00 crore (reduced from ₹25.00 crore).